Garetosmab: Mechanism of Action, Clinical Research, and Role in Body Composition Studies

What Is Garetosmab? You may see garetosmab (REGN2477) described as an experimental monoclonal antibody that binds to activin A, a signaling protein involved in inflammation, tissue scarring, and muscle regulation. Researchers designed it to block this pathway in controlled clinical settings. You cannot access it as an approved therapy. Clinical studies continue to evaluate how it affects muscle […]

Trevogrumab: What It Is, How It Works, and Its Role in Muscle Preservation Research

Understanding Trevogrumab (REGN1033) Trevogrumab (REGN1033) is an investigational monoclonal antibody that targets myostatin, a protein that restricts muscle growth. By blocking this signal, you may preserve or increase lean muscle mass in clinical settings where muscle loss is a concern. Researchers are studying trevogrumab in controlled trials, including combinations with GLP-1 receptor agonists for weight management. It does not […]

Phase 2 Courage Trial GLP-1 Receptor Agonist-Induced Weight Loss Preserving Lean Mass: Clinical Insights And Implications

GLP-1 lean mass loss has become a major concern in modern obesity treatment. While GLP-1 receptor agonists like semaglutide drive significant fat reduction, emerging data from the Phase 2 COURAGE trial suggests that preserving lean mass may be the next evolution in weight-loss therapy. Semaglutide alone led to meaningful weight reduction, but about one-third of […]